香港联交所最新数据显示，11月19日，Wang Philip Li增持百心安-B(02185)1万股，每股作价7港元，总 金额约为7万港元。增持后最新持股数目约为8493.77万股，持股比例为36.04%。 ...

智通财经APP获悉，香港联交所最新数据显示，11月19日，Wang Philip Li增持百心安-B(02185)1万股， 每股作价7港元，总金额约为7万港元。增持后最新持股数目约为8493.77万股，持股比例为36.04%。 ...

香港联交所最新数据显示，11月17日，Wang Philip Li增持百心安-B(02185)1万股，每股作价7.16港元， 总金额7.16万港元。增持后最新持股数目为8491.77万股，持股比例为36.03%。 ...

智通财经APP获悉，香港联交所最新数据显示，11月17日，Wang Philip Li增持百心安-B(02185)1万股， 每股作价7.16港元，总金额7.16万港元。增持后最新持股数目为8491.77万股，持股比例为36.03%。 ...

香港联交所最新数据显示，11月13日，董事长Wang Philip Li增持百心安-B(02185)1万股，每股作价7.18 港元，总金额约7.18万港元。增持后最新持股数目约为8489.77万股，持股比例为36.02%。 ...

智通财经APP获悉，香港联交所最新数据显示，11月13日，董事长Wang Philip Li增持百心安-B(02185)1 万股，每股作价7.18港元，总金额约7.18万港元。增持后最新持股数目约为8489.77万股，持股比例为 36.02%。 ...

Group 1 - The latest shareholder equity disclosure for Yaoshibang (09885) and Baixinan-B (02185) was conducted on November 7, 2025 [1] - Chen Fei increased his holdings in Yaoshibang from 8.3 million shares to 8.5 million shares, representing a holding percentage change from 1.22% to 1.25% [2] - Wang Philip Li maintained his holdings in Baixinan-B at 84.84 million shares, with a consistent holding percentage of 35.99% [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海百心安生物技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02185 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 235,703,422 | RMB | | 1 | RMB | | 235,703,422 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 235,703,422 | RMB | | 1 | RMB | ...

Core Viewpoint - The company announced that its subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully registered the Iberis® RDN system with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) [1] Group 1: Product Development - The Iberis® RDN system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - TRA enhances the safety, efficacy, and cost-effectiveness of RDN procedures [1] Group 2: Strategic Partnerships - The company has formed a strategic partnership with Bosheng International Group Limited to commercialize the Iberis® RDN system across multiple regions, including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM) [1] Group 3: Regulatory Milestones - The Iberis® RDN system received CE marking in Europe in 2016, indicating its compliance with health, safety, and environmental protection standards [1]

Core Insights - The company Baixinan-B (02185) announced that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully registered the Iberis Renal Denervation (RDN) system with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) [1] - Antong has formed a strategic partnership with Bosheng International Group Ltd. for the commercialization of the Iberis RDN system across multiple regions, including the EU, Asia-Pacific, and Latin America [1] - The Iberis RDN system is the only RDN product globally approved for both transradial access (TRA) and transfemoral access (TFA), enhancing safety, efficacy, and cost-effectiveness of the procedure [1] Company Overview - Bosheng is a Bermuda-registered company and a subsidiary of Shenzhen Stock Exchange-listed Blue Sail Medical Co., Ltd. (stock code: 002382), focusing on cardiovascular business [2] - Bosheng operates globally with its headquarters in Singapore and European headquarters in Morges, Switzerland, aiming to meet healthcare needs through a combination of direct sales and a global distribution network [2] - The company is committed to supporting medical education and advancing patient care by organizing training courses, scientific summits, and related activities at international and national levels [2]